Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2012. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific transaction notification and does not contain comprehensive financial statements.
Material Changes
The filing details a revaluation of the cash element of a notional investment held within the US Retirement Savings Plan. This resulted in an increase in the notional allocation of GSK American Depositary Shares (ADSs) on October 12, 2012, at a price of $45.83 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Date: October 12, 2012.
- Transaction Price: $45.83 per ADS.
- Beneficiary: Dr. K. Slaoui (Connected Person) received an increase of 5 ADSs.
- Director Status: Dr. M. M. Slaoui had no change in notional allocation (-).
- Plan Type: US Retirement Savings Plan (notional investment in GSK ADSs).